Drug Profile
Research programme: LSD1 inhibitors - Mirati Therapeutics
Alternative Names: Lysine-specific demethylase 1 inhibitors - Mirati TherapeuticsLatest Information Update: 25 Jan 2024
Price :
$50
*
At a glance
- Originator Mirati Therapeutics
- Class Antineoplastics
- Mechanism of Action Lysine specific demethylase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 23 Jan 2024 Mirati Therapeutics has been acquired by Bristol-Myers Squibb
- 27 Sep 2023 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 28 Feb 2021 No recent reports of development identified for preclinical development in Cancer in USA